* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Characterization and prediction of drug binding sites in proteins
G protein–coupled receptor wikipedia , lookup
Interactome wikipedia , lookup
Paracrine signalling wikipedia , lookup
Multi-state modeling of biomolecules wikipedia , lookup
Drug discovery wikipedia , lookup
Metalloprotein wikipedia , lookup
Protein–protein interaction wikipedia , lookup
Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup
Protein purification wikipedia , lookup
Western blot wikipedia , lookup
Proteolysis wikipedia , lookup
Signal transduction wikipedia , lookup
Two-hybrid screening wikipedia , lookup
Clinical neurochemistry wikipedia , lookup
• • • • • • Background Goals Methods Results Conclusions Implications • Proteins – organic compounds that constitute the basic functional and computational unit in the cell. They are able to bind other molecules specifically and tightly. • Pocket – The region of the protein responsible for binding. • Ligand – Substance that is able to bind to a biomolecule. • Drug – Substance that alters normal body function. • Most drugs achieve their effects by binding to a protein at a specific binding site and modifying its activity. • One may want a drug that binds to a specific location in a protein to prevent side effects. • Identifying those binding sites in proteins experimentally is time & resource consuming. This will shorten the drug development time significantly… • Collecting data – Pocket creation • Choosing attributes & analysis of pockets accordingly • Machine Learning Choosing drugs (ligands): Choosing Proteins: Docking algorithm: method to predict binding orientation. •Count the number of each amino acid. •Charge in physiological PH. •Shape matching = •Connectivity = With : •Accessibility calculation is done by simulation of rolling water molecules over the protein surface. With : •Accessibility difference of protein atoms before binding the ligand and after. •Accessibility difference of ligand atoms before binding to the pocket and after. With HBPLUS: •Number of hydrogen bonds between ligand and pocket. Positive set size: 285 Negative set size: ~10,600 Number of Attributes: 26 With WEKA – using LibSVM: Training: True: 200 Data False1,000-10,000 Testing: True: 85 False: 544-9,544 Precision/Recall change in the Positive Set 1.2 Precision/Recall Value 1 0.8 0.6 recall Precision 0.4 0.2 0 0 2000 4000 6000 Learning Set Size 8000 10000 12000 Recall/Precision Change in the Negative Set 1.02 1 0.98 Recall/Precision Value 0.96 recall 0.94 precision 0.92 0.9 0.88 0.86 0 2000 4000 6000 Learning Set Size 8000 10000 12000 ROC Graph 0.5 0.45 0.4 True Positive Rate 0.35 0.3 0.25 TP 0.2 0.15 0.1 0.05 0 -0.002 0 0.002 0.004 0.006 0.008 False Positive Rate 0.01 0.012 0.014 0.016 •We were able to distinguish between real & non-biological binding sites without using computationally expensive energy functions or evolutionary conservation. •It is not possible to distinguish between binding sites with PatchDock alone. •Using the combination of simple and computationally “cheap” tools such as SVM, PatchDock and the algorithms for pocket analysis mentioned earlier, it is possible to give a good prediction regarding the nature of the binding site. •The advantage of the method is its simplicity: Taking the best docking conformations and comparing with characteristics of real and non-biological binding sites. (No need to compare entire proteins). •The few negative binding sites classified as positives may be potentially real binding sites. (Need to be checked experimentally). The method can be improved and refined: •More attributes •More drugs and proteins •Analysis of attribute significance •Bigger learning set •Bigger positive set in relation to the negative set in the learning set (help the learning algorithm) •The tool can be used to check possible side effects during drug development. •Drug Repurposing - Find new targets for existing drugs. •Can significantly shorten the drug toxicity check during development. •Dr. Yanay Ofran •Dr. Olga Leiderman •Dr. Guy Nimrod •Vered Kunik •Rotem Snir •Sivan Ophir For your dedicated help!